Lucida Medical

Lucida Medical’s pioneering new AI platform, Pi™ is designed to help improve early detection and treatment and reduce the number of cancer-free patients going through more invasive investigative procedures – as well as potentially saving the NHS time and money.

Lucida Medical CEO, Dr Antony Rix. Courtesy – Lucida Medical.

Pi™ is built using Lucida Medical’s proprietary AI technology which has been trained to identify prostate cancer from MRI scans.

Preliminary analysis suggests the software has accuracy comparable to expert radiologists, according to results presented at the 2023 International Cancer Imaging Society annual meeting from a diverse group of six NHS hospitals participating in the PAIR-1 clinical study.

Lucida Medical was founded in 2019 by CEO, Dr Antony Rix and Chief Medical Officer Professor Evis Sala. Dr Rix has spent the last 30 years researching, working and building companies in artificial intelligence, signal processing and software. Professor Sala is a Board Certified radiologist and an expert in cancer imaging, radiology and artificial intelligence in healthcare. She serves as Chair of Radiology at Polyclinico Gemelli in Rome, Italy’s leading cancer hospital.

Newsdesk

news@businessweekly.co.uk